{
  "report_rows": [
    {
      "kpi": "Q2 2026 Adjusted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$2.00 vs. cons $1.96",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 Total Revenue",
      "prediction": "BEAT",
      "answer": "pred ~$10.85B vs. cons $10.72B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Americas Materials Solutions Segment Revenue",
      "prediction": "BEAT",
      "answer": "pred ~$5.05B vs. cons $4.94B",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 Adjusted EBITDA Guidance",
      "prediction": "BETTER",
      "answer": "guide ~$8.4B vs. cons $8.31B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Diluted EPS Guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$5.90 vs. cons $5.92 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Share Buyback/Capital Return Cadence Post-Arcosa",
      "prediction": "LOWER",
      "answer": "guide ~$0 new tranche vs. cons ~$300M continued buyback (2H2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 2.0,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 0.4,
  "day5_path": "FADE",
  "day5_rationale": "An EPS/revenue beat and reaffirmed-to-slightly-raised FY26 EBITDA guidance should spark an initial relief rally given the stock's ~20% YTD de-rating, but the pause in buybacks post-July and confirmation that Arcosa financing (term loan + remaining bridge) will raise pro-forma interest expense in 2H26/2027 should prompt analysts to trim out-quarter EPS estimates even after the headline beat, causing the pop to partially fade over the week as the leverage/dilution math gets modeled in.",
  "day5_confidence": "LOW"
}